Title |
Cardioprotective efficacy depends critically on pharmacological dose, duration of ischaemia, health status of animals and choice of anaesthetic regimen: a case study with folic acid
|
---|---|
Published in |
Journal of Translational Medicine, November 2014
|
DOI | 10.1186/s12967-014-0325-8 |
Pubmed ID | |
Authors |
Coert J Zuurbier, Andre Heinen, Anneke Koeman, Roy Stuifbergen, Theodorus BM Hakvoort, Nina C Weber, Markus W Hollmann |
Abstract |
BackgroundAcute, high-dose folic acid (FA) administration has recently been shown to possess unprecedented effective cardioprotection against ischaemia/reperfusion (I/R) injury. Here we explore the translation potential of FA as treatment modality for cardiac I/R.MethodsDependency of FA protection on dose, ischaemia duration, and eNOS was examined in an isolated mouse heart I/R model, whereas dependency on animal health status and anaesthesia was examined in an in vivo rat model of regional cardiac I/R.Results50 ¿M FA provided maximal reduction (by 95%) of I/R-induced cell death following 25 min ischaemia in isolated wild-type hearts, with protection associated with increased coupled eNOS protein. No protection was observed with 35 min I or in eNOS¿/¿ hearts. Acute intravenous administration of FA during a 25 min ischaemic period reduced infarct size by 45% in in vivo pentobarbital-anaesthetised young, healthy rats. FA did not reduce infarct size in aged or pre-diabetic rats, although it did preserve hemodynamics in the pre-diabetic rats. Finally, using a clinically-relevant anaesthetic regimen of fentanyl-propofol anaesthesia, FA treatment was ineffective in young, aged and pre-diabetic animals.ConclusionsThe protective potential of an initially promising cardioprotective treatment of high dose FA against cardiac I/R infarction, is critically dependent on experimental conditions with relevance to the clinical condition. Our data indicates the necessity of expanded pre-clinical testing of cardioprotective interventions before embarking on clinical testing, in order to prevent too many ¿lost-in-translation¿ drugs and unnecessary clinical studies. |
Twitter Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 17 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 4 | 24% |
Researcher | 3 | 18% |
Other | 2 | 12% |
Student > Ph. D. Student | 1 | 6% |
Librarian | 1 | 6% |
Other | 2 | 12% |
Unknown | 4 | 24% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 5 | 29% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 12% |
Biochemistry, Genetics and Molecular Biology | 2 | 12% |
Agricultural and Biological Sciences | 2 | 12% |
Chemical Engineering | 1 | 6% |
Other | 0 | 0% |
Unknown | 5 | 29% |